{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-093946","form_type":"8-K","ticker":"ASMB","cik":"0001426800","company_name":"ASSEMBLY BIOSCIENCES, INC.","filed_at":"2024-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.021480+00:00","generated_at":"2026-05-31T10:46:32.484741+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Assembly Biosciences Q2 2024 net loss $11.2M; cash runway into Q1 2026","bullets":["Cash, equivalents and marketable securities $109.2M as of June 30, 2024, down from $113.0M at March 31, 2024.","Revenue from Gilead collaboration $8.5M in Q2 2024 (vs. $0 in Q2 2023); R&D expenses $16.3M (up from $12.5M).","Net loss $11.2M ($1.98 per share) vs. $16.9M ($3.88) in Q2 2023; net loss improved on higher revenue.","Phase 1a/b dosing initiated for ABI-5366 (genital herpes) and Phase 1b for ABI-4334 (chronic HBV infection).","Two additional candidates (ABI-1179, ABI-6250) expected to enter clinic by end of 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-093946","json":"https://secwatch.observer/filing/0000950170-24-093946.json","markdown":"https://secwatch.observer/filing/0000950170-24-093946.md","text":"https://secwatch.observer/filing/0000950170-24-093946.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1426800/000095017024093946/0000950170-24-093946-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1426800/000095017024093946/asmb-20240808.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T10:46:32.484741+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}